These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

869 related articles for article (PubMed ID: 28521640)

  • 1. Antibody-mediated immunotherapy against chronic hepatitis B virus infection.
    Gao Y; Zhang TY; Yuan Q; Xia NS
    Hum Vaccin Immunother; 2017 Aug; 13(8):1768-1773. PubMed ID: 28521640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen.
    Zhang TY; Yuan Q; Zhao JH; Zhang YL; Yuan LZ; Lan Y; Lo YC; Sun CP; Wu CR; Zhang JF; Zhang Y; Cao JL; Guo XR; Liu X; Mo XB; Luo WX; Cheng T; Chen YX; Tao MH; Shih JW; Zhao QJ; Zhang J; Chen PJ; Yuan YA; Xia NS
    Gut; 2016 Apr; 65(4):658-71. PubMed ID: 26423112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice.
    Zhang TY; Guo XR; Wu YT; Kang XZ; Zheng QB; Qi RY; Chen BB; Lan Y; Wei M; Wang SJ; Xiong HL; Cao JL; Zhang BH; Qiao XY; Huang XF; Wang YB; Fang MJ; Zhang YL; Cheng T; Chen YX; Zhao QJ; Li SW; Ge SX; Chen PJ; Zhang J; Yuan Q; Xia NS
    Gut; 2020 Feb; 69(2):343-354. PubMed ID: 30926653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B.
    Le Bert N; Salimzadeh L; Gill US; Dutertre CA; Facchetti F; Tan A; Hung M; Novikov N; Lampertico P; Fletcher SP; Kennedy PTF; Bertoletti A
    J Hepatol; 2020 Jan; 72(1):34-44. PubMed ID: 31348999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure.
    Walsh R; Hammond R; Yuen L; Deerain J; O'Donnell T; Leary T; Cloherty G; Gaggar A; Kitrinos K; Subramanian M; Wong D; Locarnini S
    Liver Int; 2019 Nov; 39(11):2066-2076. PubMed ID: 31379058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulated Response of Follicular Helper T Cells to Hepatitis B Surface Antigen Promotes HBV Persistence in Mice and Associates With Outcomes of Patients.
    Wang X; Dong Q; Li Q; Li Y; Zhao D; Sun J; Fu J; Meng F; Lin H; Luan J; Liu B; Wang M; Wang FS; He F; Tang L
    Gastroenterology; 2018 Jun; 154(8):2222-2236. PubMed ID: 29544722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
    Martin P; Dubois C; Jacquier E; Dion S; Mancini-Bourgine M; Godon O; Kratzer R; Lelu-Santolaria K; Evlachev A; Meritet JF; Schlesinger Y; Villeval D; Strub JM; Van Dorsselaer A; Marchand JB; Geist M; Brandely R; Findeli A; Boukhebza H; Menguy T; Silvestre N; Michel ML; Inchauspé G
    Gut; 2015 Dec; 64(12):1961-71. PubMed ID: 25429051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B Virus Surface Antigen Activates Myeloid Dendritic Cells via a Soluble CD14-Dependent Mechanism.
    van Montfoort N; van der Aa E; van den Bosch A; Brouwers H; Vanwolleghem T; Janssen HLA; Javanbakht H; Buschow SI; Woltman AM
    J Virol; 2016 Jul; 90(14):6187-6199. PubMed ID: 27099316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response.
    Ma Z; Zhang E; Gao S; Xiong Y; Lu M
    Front Immunol; 2019; 10():2308. PubMed ID: 31608073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New broadly reactive neutralizing antibodies against hepatitis B virus surface antigen.
    Kucinskaite-Kodze I; Pleckaityte M; Bremer CM; Seiz PL; Zilnyte M; Bulavaite A; Mickiene G; Zvirblis G; Sasnauskas K; Glebe D; Zvirbliene A
    Virus Res; 2016 Jan; 211():209-21. PubMed ID: 26541316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients.
    Huang D; Sansas B; Jiang JH; Gong QM; Jin GD; Calais V; Yu DM; Zhu MY; Wei D; Zhang DH; Inchauspé G; Zhang XX; Zhu R
    J Viral Hepat; 2017 Nov; 24 Suppl 1():66-74. PubMed ID: 29082648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection.
    Meng Z; Chen Y; Lu M
    Front Immunol; 2019; 10():3127. PubMed ID: 32117201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant.
    Hsu HY; Chang MH; Ni YH; Jeng YM; Chiang CL; Chen HL; Wu JF; Chen PJ
    J Infect Dis; 2013 Apr; 207(7):1047-57. PubMed ID: 23300165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antiviral - passive - active immunization ("sandwich") therapeutic strategy for functional cure of chronic hepatitis B in mice.
    Shi B; Wu Y; Wang C; Li X; Yu F; Wang B; Yang Z; Li J; Liang M; Wen Y; Ying T; Yuan Z
    EBioMedicine; 2019 Nov; 49():247-257. PubMed ID: 31680000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel targets for hepatitis B virus therapy.
    Testoni B; Durantel D; Zoulim F
    Liver Int; 2017 Jan; 37 Suppl 1():33-39. PubMed ID: 28052622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a hepatitis B virus neutralizing chimeric monoclonal antibody recognizing escape mutants of the viral surface antigen (HBsAg).
    Golsaz-Shirazi F; Amiri MM; Farid S; Bahadori M; Bohne F; Altstetter S; Wolff L; Kazemi T; Khoshnoodi J; Hojjat-Farsangi M; Chudy M; Jeddi-Tehrani M; Protzer U; Shokri F
    Antiviral Res; 2017 Aug; 144():153-163. PubMed ID: 28641998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A large-scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies.
    Xiang Y; Chen P; Xia JR; Zhang LP
    Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28252163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection.
    Le Bert N; Gill US; Hong M; Kunasegaran K; Tan DZM; Ahmad R; Cheng Y; Dutertre CA; Heinecke A; Rivino L; Tan A; Hansi NK; Zhang M; Xi S; Chong Y; Pflanz S; Newell EW; Kennedy PTF; Bertoletti A
    Gastroenterology; 2020 Aug; 159(2):652-664. PubMed ID: 32302614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.